| Biomarker ID | 1524 |
| PMID | 25170626 |
| Year | 2014 |
| Biomarker | Oligophrenin-1 (OPHN1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: Univariate Analysis: 2.361 (95% CI: 1.229–4.656); Multivariate Analysis: 2.372 (95% CI: 1.225–4.713) |
| Effect on Pathways | Pathways include: Rho cell motility signaling pathway, RhoA activity regulation, Rho GTPase cycle, Signal transduction |
| Experiment | Stage pT2 Vs Stage pT3 |
| Type of Biomarker | Prognostic |
| Cohort | 141 Prostate cancer samples were chosen for the analysis. 83 had Stage pt2 and rest had stage pT3 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | univariate: p=0.0099; Multivariate: 0.0104 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |